AUP:CA:TSX-Aurinia Pharmaceuticals Inc (CAD)

COMMON STOCK | Biotechnology | TSX

Last Closing Price

CAD 15.79

Change

+0.04 (+0.25)%

Market Cap

CAD 2.01B

Volume

0.04M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
TRIL:CA Trillium Therapeutics Inc

+0.15 (+1.17%)

CAD1.32B 1.80 N/A
APS:CA Aptose Biosciences Inc

+0.38 (+5.86%)

CAD0.58B N/A N/A
LMNL:CA Liminal BioSciences Inc

N/A

CAD0.54B 1.28 N/A
BLU:CA BELLUS Health Inc

-0.15 (-2.65%)

CAD0.44B N/A N/A
MDNA:CA Medicenna Therapeutics Corp

-0.04 (-0.79%)

CAD0.27B 5.40 N/A
IMV:CA IMV Inc

+0.05 (+1.43%)

CAD0.24B -99,999.99 N/A
ONC:CA Oncolytics Biotech Inc

-0.16 (-4.15%)

CAD0.21B N/A N/A
ATE:CA Antibe Therapeutics Inc

-0.03 (-0.66%)

CAD0.21B N/A N/A
RVX:CA Resverlogix Corp

+0.01 (+1.15%)

CAD0.21B 62.86 26.37
FRX:CA Fennec Pharmaceuticals Inc

+0.57 (+7.59%)

CAD0.20B 30.20 N/A

ETFs Containing AUP:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.08% 28% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.08% 28% F 7% F
Trailing 12 Months  
Capital Gain -28.06% 32% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -28.06% 32% F 2% F
Trailing 5 Years  
Capital Gain 315.53% 92% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 315.53% 92% A- 95% A
Average Annual (5 Year Horizon)  
Capital Gain 66.12% 68% D+ 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.12% 68% D+ 97% A+
Risk Return Profile  
Volatility (Standard Deviation) 80.53% 58% F 8% F
Risk Adjusted Return 82.11% 95% A 86% B
Market Capitalization 2.01B 100% A+ 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.99 65% D 25% F
Price / Cash Flow Ratio -28.73 75% C 91% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -29.07% 93% A 15% F
Return on Invested Capital -28.59% 65% D 7% F
Return on Assets -16.54% 85% B 7% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.20 55% F 47% F
Short Percent N/A N/A N/A N/A N/A
Beta 0.34 71% C- 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector